Paul Emery is an expert in Rheumatology at Leeds Teaching Hospitals NHS Trust (United Kingdom). As of October 2026, ScienceLeadR ranks Paul Emery in the top 1% of experts worldwide for Synovitis, Arthritis and Autoimmune Diseases. Paul Emery has authored 1,014 publications, the most recent in 2026, and is an investigator in 51 clinical trials. SLR score: 3,487 (community average: 125). How the SLR is computed.

LeadR Profile

Paul Emery Leeds Teaching Hospitals NHS Trust United Kingdom
3 487 ScienceLeadR Reputation 3487
Network Map

Rheumatology

Subspecialties: Internal Medicine - Dermatology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1999 - 2026

Source: PubMed

University of Leeds

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Corrigendum to 'Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study' [EULAR Rheumatology Open 1 (2025) 282-290].
PMID 42871760 — rheumatology, safety, cross-over studies, biosimilar pharmaceuticals
EULAR Rheumatol Open20260
Targeted anti-CCP testing to identify people at risk of rheumatoid arthritis in primary care: an early economic evaluation.
PMID 42819732 — research design, rheumatology, arthritis, signs and symptoms, arthritis, rheumatoid
Rheumatol Adv Pract20260
First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes.
PMID 42755040 — arthritis, rheumatic diseases, network meta-analysis, arthritis, rheumatoid, therapeutics, janus kinase inhibitors, methotrexate
Rheumatology (Oxford)20260
Risk prediction rules in individuals at risk of rheumatoid arthritis: systematic review and validation using the APIPPRA cohort.
PMID 42676706 — arthritis, arthritis, rheumatoid
EULAR Rheumatol Open20260
DNA hypo-methylation of the TNFΑ gene predicts response to methotrexate in rheumatoid arthritis but not in psoriatic arthritis.
PMID 42664067 — treatment outcome, genes, arthritis, psoriatic, arthritis, biomarkers, rheumatic diseases, arthritis, rheumatoid, diagnosis, therapeutics, dna, methotrexate
Rheumatology (Oxford)20260

Clinical Studies 51

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7 Study Chair: 2

By phase:

Phase 3 25
Phase 4 11
Phase 2 8
N/A 6
Phase 1/Phase 2 1

By status:

Completed 46
Unknown 5

By type:

Interventional 47
Observational 4

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 2
multicentric5to9 1
multicentricup10 38

Main Topics

Cohort/Consortium Investigators 32

LeadR Networks

Main global connection map